Citizens downgrades KKR stock rating to Market Perform on valuation concerns

Citizens downgraded KKR & Co. to Market Perform from Market Outperform, citing significant valuation concerns after the stock's 64% surge from April lows, which has led to it trading 50% above its 5-year historical price-to-next-twelve-months earnings average. The firm also noted its 2026 EPS estimate is 6% below consensus and management targets, suggesting a rebalanced risk/reward and potential for lower forward expectations. Despite this, Morgan Stanley and Piper Sandler both maintain Overweight ratings with $150 price targets, while KKR continues strategic activities including the acquisition of ProTen and exploring a €10 billion sale of its Masorange stake.

Analysis

KKR & Co. faces a diverging analyst outlook following a downgrade from Citizens to Market Perform, which primarily cites valuation concerns. The stock's 64% appreciation since its April lows has pushed its valuation to approximately 50% above its 5-year historical average price-to-next-twelve-months earnings ratio, a significant premium compared to the 20% average for its peers. Fueling this caution, Citizens' 2026 EPS estimate of $6.25 is 6% below consensus and falls short of management's $7-$8 target range, with the firm noting its estimate has already declined 10% year-to-date. This perspective is further supported by InvestingPro data indicating four analysts have recently revised earnings expectations downward. In stark contrast, Morgan Stanley and Piper Sandler both maintain Overweight ratings and a $150 price target, with Morgan Stanley designating KKR a "Top Pick" amid a recovering capital market environment. Operationally, KKR remains active, agreeing to acquire ProTen in Australia and exploring a potential €10 billion sale of its Masorange stake, though its takeover bid for Assura has not yet gained traction.

Key Decisions for Investors

• Investors should weigh the significant valuation risk highlighted by Citizens against the bullish theses from Morgan Stanley and Piper Sandler, recognizing the clear divergence in Street sentiment.
• It is critical to monitor upcoming earnings releases for any downward revision to forward guidance, particularly regarding management's $7-$8 EPS target, which would validate the concerns about a potential expectations reset.
• Portfolio managers should track progress on key M&A catalysts, as the successful execution of the €10 billion Masorange stake sale could unlock substantial value and counter the current valuation narrative.